The mental health biotech sub-sector includes companies developing drugs for ADHD, depression, bipolar disorder, schizophrenia, migraines, alzheimer's, and other central nervous system conditions. Due to growing public awareness, Todd Hagopian believes these stocks are reaching a tipping point.
The mental health biotech sub-sector includes companies developing drugs for ADHD, depression, bipolar disorder, schizophrenia, migraines, alzheimer's, and other central nervous system conditions. Due to growing public awareness, Todd Hagopian believes these stocks are reaching a tipping point.
Share this Article
Recommended